Abstract：Objective : To investigate the efficacy and safety of immunosuppressant for infants after liver transplantation.Methods : A retrospective analysis was performed in 84 infants undergoing liver transplantation in our hospital during 2013.6~ 2015.6, and application and adverse reaction of immunosuppressant were analyzed. Results : All the infants have received tacrolimus combined with methylprednisolone, the initial dose of FK506 was (0.18±0.08) mg?kg-1?d-1. 70 patients kept using the same bigeminy immunosuppressant therapy at discharge, and the discharge dose of FK506 was (0.24±0.17) mg?kg-1?d-1. The range of effective plasma concentration of FK506 was 6-11μg?L-1. Patient survival, infection rate and acute rejection were 89.3%, 71.43% and 14.29% respectively during the hospitalization period. The average blood concentration of FK506 was (5.69±2.38) μg?L-1 when acute rejection occurred, and 10 in 12 cases (83.3%) were below 8 μg?L-1. There were 39 cases drug adverse reaction which involved 31 infants, and the incidence of adverse reaction was 36.9% (31/84). The incidence of gastrointestinal tract reaction, CNS reaction, transaminase elevation and renal dysfunction were 15.48%, 7.14%,8.3% and 33.57%, respectively. The average blood concentration of FK506 was (12.77±4.98) μg?L-1 when adverse reaction occurred, and 31 in 39 cases (79.5%) were over 8.5 μg?L-1. Conclusion : The bigeminy immunosuppressant protocol based on tacrolimus is effective and safe in infants after liver transplantation, and there are some differences of the dosage and the effective plasma concentration of FK506 between infants and adults.
2016, Vol. 14 
